{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:03:40Z","timestamp":1782925420583,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102385","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:05:28Z","timestamp":1749816328000},"page":"102385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-5930","authenticated-orcid":false,"given":"Emre","family":"Yeked\u00fcz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-4035","authenticated-orcid":false,"given":"Martin","family":"Zarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-9312","authenticated-orcid":false,"given":"Eddy","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3424-6585","authenticated-orcid":false,"given":"Razane El Hajj","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee Maria","family":"Saliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8640-1636","authenticated-orcid":false,"given":"Clara","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9922","authenticated-orcid":false,"given":"Marc","family":"Machaalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashad","family":"Nawfal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102385_bib0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clgc.2025.102385_bib0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102385_bib0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102385_bib0004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102385_bib0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102385_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000953","article-title":"Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis","volume":"8","author":"Dizman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2025.102385_bib0007","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41588-024-01899-0","article-title":"Five latent factors underlie response to immunotherapy","volume":"56","author":"Usset","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2025.102385_bib0008","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41419-024-06641-6","article-title":"Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review","volume":"15","author":"Golonko","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clgc.2025.102385_bib0009","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2025.102385_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2025.102385_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2025.102385_bib0012","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.hoc.2023.05.021","article-title":"Emerging biomarkers of response to systemic therapies in metastatic clear cell renal cell carcinoma","volume":"37","author":"Labaki","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clgc.2025.102385_bib0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2025.102385_bib0014","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1634\/theoncologist.2020-0014","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability-high end-stage cancers and poor performance status related to high disease burden","volume":"25","author":"Pietrantonio","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2025.102385_bib0015","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41571-019-0249-6","article-title":"Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms","volume":"16","author":"Renzi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102385_bib0016","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102385_bib0017","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1634\/theoncologist.2017-0687","article-title":"Characterization of comorbidities limiting the recruitment of patients in early phase clinical trials","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2025.102385_bib0018","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/CJI.0000000000000366","article-title":"Immunotherapy utilization among patients with metastatic NSCLC: impact of comorbidities","volume":"44","author":"Zhang","year":"2021","journal-title":"J Immunother"},{"key":"10.1016\/j.clgc.2025.102385_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.12061","article-title":"Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy","volume":"41","author":"Faucheux","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clgc.2025.102385_bib0020","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/hed.27502","article-title":"Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy","volume":"45","author":"Guller","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.clgc.2025.102385_bib0021","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00262-023-03371-0","article-title":"Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy","volume":"72","author":"Johns","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2025.102385_bib0022","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.922576","article-title":"Effect of comorbidity on outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD1 immunotherapy","volume":"26","author":"Zeng","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clgc.2025.102385_bib0023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clgc.2025.102385_bib0024","article-title":"National Health and Nutrition Examination Survey 2017-March 2020 prepandemic Data files-development of files and prevalence estimates for selected health outcomes","volume":"158","author":"Stierman","year":"2021","journal-title":"Natl Health Stat Report"},{"key":"10.1016\/j.clgc.2025.102385_bib0025","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.clgc.2025.102385_bib0026","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2022.05.019","article-title":"Preexisting comorbidities shape the immune response associated with severe COVID-19","volume":"150","author":"Kreutmair","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clgc.2025.102385_bib0027","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2025.102385_bib0028","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature13398","article-title":"High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity","volume":"514","author":"Schulz","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2025.102385_bib0029","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aar3318","article-title":"Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection","volume":"359","author":"Thaiss","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clgc.2025.102385_bib0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41586-020-2881-9","article-title":"Host variables confound gut microbiota studies of human disease","volume":"587","author":"Vujkovic-Cvijin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2025.102385_bib0031","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/jnci\/djt300","article-title":"Human gut microbiome and risk for colorectal cancer","volume":"105","author":"Ahn","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2025.102385_bib0032","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41522-024-00511-x","article-title":"Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinoma","volume":"10","author":"Cai","year":"2024","journal-title":"NPJ Biofilm Microbio"},{"key":"10.1016\/j.clgc.2025.102385_bib0033","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clgc.2025.102385_bib0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-kappaB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clgc.2025.102385_bib0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/10781552211012038","article-title":"The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy","volume":"28","author":"Guven","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clgc.2025.102385_bib0036","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clgc.2025.102385_bib0037","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/PPO.0000000000000484","article-title":"Immunotherapy use in patients with lung cancer and comorbidities","volume":"26","author":"von Itzstein","year":"2020","journal-title":"Cancer J"},{"key":"10.1016\/j.clgc.2025.102385_bib0038","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2217\/imt-2023-0270","article-title":"Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events","volume":"16","author":"Onur","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clgc.2025.102385_bib0039","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clgc.2021.09.005","article-title":"Early clinical experience with Cabozantinib for advanced renal cell carcinoma in the UK: real-world treatment pathways and clinical outcomes","volume":"20","author":"Venugopal","year":"2022","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1016\/j.clgc.2025.102385_bib0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102385_bib0041","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccell.2022.06.005","article-title":"Sex and cancer immunotherapy: current understanding and challenges","volume":"40","author":"Pala","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T21:14:18Z","timestamp":1752700458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000850"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102385","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102385"}}